리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2024년 08월
페이지 정보:영문 192 Pages
라이선스 & 가격 (부가세 별도)
한글목차
POC 지질검사의 시장은 2030년까지 3억 2,710만 달러에 달할 전망입니다.
2023년에 2억 6,330만 달러로 추정된 POC 지질검사 시장은 예측 기간 동안 복합 연간 성장률(CAGR) 3.1%로 성장하여 2030년에는 3억 2,710만 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 고지혈증 애플리케이션은 복합 연간 성장률(CAGR) 2.9%로 성장을 지속하고, 분석 기간이 끝날 때 9,700만 달러에 도달할 것으로 예측됩니다. 높은 트리글리세리드 혈증 응용 분야의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 4.1%로 추정됩니다.
미국 시장은 6,920만 달러로 추정되며 중국은 복합 연간 성장률(CAGR) 5.4%로 성장할 것으로 예측됩니다.
미국의 POC 지질검사 시장은 2023년 6,920만 달러로 추정됩니다. 세계의 2위 경제대국인 중국은 예측 기간 동안 복합 연간 성장률(CAGR) 5.4%로 성장을 지속하여 2030년에는 예측 시장 규모 7,050만 달러에 달할 것으로 예측되고 있습니다. 기타 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR)은 각각 0.9%와 2.4%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 1.5%로 성장할 것으로 예측됩니다.
세계의 POC 지질 검사 시장 - 주요 동향 및 촉진요인 요약
인스턴트 헬스 인사이트 POC 지질 검사의 역할
포인트 오브 케어(POC) 지질 검사란 환자의 진료 현장에서 직접 지질 수준을 측정하는 과정을 말하며, 집중적인 검사 시설 없이도 즉시 결과를 얻을 수 있습니다. 이 검사는 일반적으로 총 콜레스테롤, 고비중 지단백질(HDL), 저비중 지단백질(LDL), 트리글리세리드와 같은 주요 지질 매개 변수를 측정하며, 이는 심혈관 건강 상태를 평가하는 데 매우 중요합니다. POC 지질검사장치는 종종 손가락을 찔러 채취한 소량의 혈액을 사용합니다. 혈액은 테스트 스트립 또는 카세트에 적용되고 비색 분석 및 바이오 센서와 같은 방법을 사용하여 휴대용 장치에서 분석됩니다. 결과를 신속하게 얻을 수 있기 때문에 건강 관리 제공업체는 신속한 임상 판단을 내릴 수 있으며 환자 관리를 강화하고 지질 이상증 및 기타 지질 관련 질환의 조기 개입을 촉진할 수 있습니다.
POC 지질 검사는 임상 현장에서 어떻게 활용되고 있는가?
임상 현장에서 POC 지질 검사는 일상적인 건강 진단 및 만성 질환 관리에 중요한 역할을합니다. 1차 케어 의사가 정기 검진 시에 이러한 검사를 이용하여 환자의 지질 수준을 모니터링함으로써 고지혈증 및 기타 심혈관계의 위험 인자를 조기에 발견할 수 있습니다. 지질이상증이 밝혀진 환자의 경우, POC 검사는 치료 효과를 추적하고 필요에 따라 약물을 조절하는 편리한 방법을 제공합니다. 응급 현장에서는 급성 관상 증후군 및 기타 심혈관계 사건이 발생한 환자의 위험 계층화에 신속한 지질 검사가 도움이 됩니다. 또한 POC 지질 검사는 검사 시설에 대한 접근이 제한되는 원격지 및 자원이 제한된 환경에서도 매우 귀중하며 환자가 필수적인 진단 서비스를 받을 수 있도록 보장합니다. POC 지질 검사의 즉각성과 편리성은 특히 신속한 임상 판단이 필요한 시나리오에서 현대 건강 관리에 필수적인 도구가 되었습니다.
POC 지질 검사 기술의 동향은?
POC 지질 검사를 지원하는 기술은 보다 정확하고 사용하기 쉽고 광범위한 건강 관리 시스템과의 통합이 요구되는 동안 지속적으로 진화하고 있습니다. 주목할만한 동향 중 하나는 검사 장비의 소형화와 휴대성입니다. 검사 장비는 점점 더 작고 사용하기 쉽고 다양한 건강 관리 환경에서 사용하기 쉽습니다. 바이오센서 기술의 진보는 이러한 장비의 감도와 특이성을 향상시켜 보다 신뢰할 수 있는 결과를 얻을 수 있게 되었습니다. 디지털 헬스 플랫폼과의 통합도 중요한 동향으로, 전자 의료 기록(EHR)에 검사 결과를 자동 업로드하고, 원격 모니터링 및 원격 의료 용도을 가능하게 합니다. 또한, 여러 건강 파라미터를 동시에 평가하고 환자의 심혈관 건강 상태를 보다 종합적으로 파악할 수 있는 멀티 분석 POC 장치의 개발에 대한 관심이 높아지고 있습니다. 이러한 기술 혁신은 POC 지질 검사에 더 접근하기 쉽고 효율적이고 유익하며 전반적인 환자 관리 및 관리를 개선하고 있습니다.
POC 지질검사 시장의 성장을 가속하는 요인은?
POC 지질 검사 시장의 성장은 신속하고 신뢰할 수 있는 진단 도구에 대한 수요 증가를 반영하는 여러 요인들에 의해 견인되고 있습니다. 심혈관 질환의 유병률의 상승과 예방 헬스케어의 세계의 중시는 중요한 촉진요인이며, 지질이상증의 조기 발견과 관리는 심혈관 리스크의 저감에 필수적이기 때문입니다. 정확성 향상, 휴대성, 디지털 헬스 시스템과의 통합 등 POC 검사 장비의 기술적 진보는 다양한 헬스케어 환경에서의 채용을 강화하고 있습니다. 특히 COVID-19의 유행에 대응한 원격 의료 및 원격 환자 모니터링의 이용 확대도 빈번한 대면 진료를 필요로 하지 않는 지속적인 환자 케어를 지원하기 위해 POC 지질 검사 수요를 끌어올리고 있습니다. 또한, 개인화된 의료에 대한 관심 증가는 실시간 지질 수준 평가를 기반으로 맞춤형 치료 계획을 제공하는 POC 검사의 이용을 촉구하고 있습니다. 이러한 요인은 종합적으로 POC 지질 검사 시장의 견조한 성장을 보장하고 현대 건강 관리 및 만성 질환 관리에서 중요한 역할을 강조합니다.
조사 대상 기업 예(총 42건)
A. Menarini Industrie Farmaceutiche Riunite Srl
Abaxis, Inc.
Accutech LLC
Alere, Inc.
Biochemical Systems International Srl
Bio-Rad Laboratories, Inc.
Eurotrol BV
F. Hoffmann-La Roche AG
General Life Biotechnology Co., Ltd.
Helena Laboratories Corporation
Nova Biomedical Corporation
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트(UAE)
기타 중동
아프리카
제4장 경쟁
BJH
영문 목차
영문목차
Global POC Lipid Testing Market to Reach US$327.1 Million by 2030
The global market for POC Lipid Testing estimated at US$263.3 Million in the year 2023, is expected to reach US$327.1 Million by 2030, growing at a CAGR of 3.1% over the analysis period 2023-2030. Hyperlipidemia Application, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$97.0 Million by the end of the analysis period. Growth in the Hypertriglyceridemia Application segment is estimated at 4.1% CAGR over the analysis period.
The U.S. Market is Estimated at US$69.2 Million While China is Forecast to Grow at 5.4% CAGR
The POC Lipid Testing market in the U.S. is estimated at US$69.2 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$70.5 Million by the year 2030 trailing a CAGR of 5.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.
Global POC Lipid Testing Market - Key Trends and Drivers Summarized
Instant Health Insights: The Role of POC Lipid Testing
Point-of-care (POC) lipid testing refers to the process of measuring lipid levels directly at the site of patient care, providing immediate results without the need for centralized laboratory facilities. This testing typically measures key lipid parameters, including total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides, which are critical for assessing cardiovascular health. POC lipid testing devices often use small blood samples obtained through a finger prick. The blood is applied to a test strip or cassette, which is then analyzed by a portable device using methods such as colorimetric assays or biosensors. The rapid turnaround of results allows healthcare providers to make prompt clinical decisions, enhancing patient management and facilitating early intervention in cases of dyslipidemia and other lipid-related disorders.
How Is POC Lipid Testing Utilized in Clinical Practice?
In clinical practice, POC lipid testing plays a crucial role in both routine health assessments and the management of chronic conditions. Primary care physicians use these tests during regular check-ups to monitor patients' lipid levels, enabling the early detection of hyperlipidemia and other cardiovascular risk factors. For patients with known lipid disorders, POC testing provides a convenient way to track treatment efficacy and adjust medications as needed. In emergency settings, rapid lipid testing can aid in the risk stratification of patients presenting with acute coronary syndromes or other cardiovascular events. Furthermore, POC lipid testing is invaluable in remote and resource-limited settings where access to laboratory facilities may be restricted, ensuring that patients still receive essential diagnostic services. The immediacy and convenience of POC lipid testing make it an indispensable tool in modern healthcare, particularly in scenarios requiring swift clinical decisions.
What Are the Current Trends in POC Lipid Testing Technology?
The technology behind POC lipid testing is continually advancing, driven by the need for greater accuracy, ease of use, and integration with broader healthcare systems. One notable trend is the miniaturization and portability of testing devices, which are becoming increasingly compact and user-friendly, facilitating their use in various healthcare environments. Advances in biosensor technology are enhancing the sensitivity and specificity of these devices, ensuring more reliable results. Integration with digital health platforms is another significant trend, allowing for the automatic upload of test results to electronic health records (EHRs) and enabling remote monitoring and telemedicine applications. Additionally, there is growing interest in developing multi-analyte POC devices that can assess multiple health parameters simultaneously, providing a more comprehensive overview of a patient’s cardiovascular health. These innovations are making POC lipid testing more accessible, efficient, and informative, improving overall patient care and management.
What Factors Are Driving the Growth in the POC Lipid Testing Market?
The growth in the POC lipid testing market is driven by several factors, reflecting the increasing demand for rapid and reliable diagnostic tools. The rising prevalence of cardiovascular diseases and the global emphasis on preventive healthcare are significant drivers, as early detection and management of lipid disorders are critical for reducing cardiovascular risk. Technological advancements in POC testing devices, including improved accuracy, portability, and integration with digital health systems, are enhancing their adoption across various healthcare settings. The expanding use of telemedicine and remote patient monitoring, especially in response to the COVID-19 pandemic, is also boosting demand for POC lipid testing, as it supports ongoing patient care without the need for frequent in-person visits. Additionally, the growing focus on personalized medicine is encouraging the use of POC testing to provide tailored treatment plans based on real-time lipid level assessments. These factors collectively ensure robust growth in the POC lipid testing market, underscoring its vital role in modern healthcare and chronic disease management.
Select Competitors (Total 42 Featured) -
A. Menarini Industrie Farmaceutiche Riunite Srl
Abaxis, Inc.
Accutech LLC
Alere, Inc.
Biochemical Systems International Srl
Bio-Rad Laboratories, Inc.
Eurotrol B.V.
F. Hoffmann-La Roche AG
General Life Biotechnology Co., Ltd.
Helena Laboratories Corporation
Nova Biomedical Corporation
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
POC Lipid Testing - Global Key Competitors Percentage Market Share in 2024 (E)
Global Economic Update
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for POC Lipid Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Hyperlipidemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Hyperlipidemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Hyperlipidemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Hypertriglyceridemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Hypertriglyceridemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Hypertriglyceridemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Familial Hypercholesterolemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Familial Hypercholesterolemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Familial Hypercholesterolemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Hyperlipoproteinemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 14: World Historic Review for Hyperlipoproteinemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 15: World 16-Year Perspective for Hyperlipoproteinemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Tangier Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 17: World Historic Review for Tangier Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 18: World 16-Year Perspective for Tangier Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 20: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 21: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 22: World POC Lipid Testing Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 23: USA Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 24: USA Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 25: USA 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
CANADA
TABLE 26: Canada Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 27: Canada Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 28: Canada 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
JAPAN
POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 29: Japan Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 30: Japan Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 31: Japan 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
CHINA
POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 32: China Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 33: China Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 34: China 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
EUROPE
POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 35: Europe Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 36: Europe Historic Review for POC Lipid Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 37: Europe 16-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 38: Europe Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: Europe Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: Europe 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
FRANCE
POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 41: France Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 42: France Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: France 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
GERMANY
POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 44: Germany Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: Germany Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: Germany 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
ITALY
TABLE 47: Italy Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 48: Italy Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: Italy 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
UNITED KINGDOM
POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 50: UK Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: UK Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: UK 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
SPAIN
TABLE 53: Spain Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 54: Spain Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 55: Spain 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
RUSSIA
TABLE 56: Russia Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: Russia Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 58: Russia 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 59: Rest of Europe Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 60: Rest of Europe Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 61: Rest of Europe 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
ASIA-PACIFIC
POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 63: Asia-Pacific Historic Review for POC Lipid Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 64: Asia-Pacific 16-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 66: Asia-Pacific Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 67: Asia-Pacific 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
AUSTRALIA
POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 68: Australia Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: Australia Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 70: Australia 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
INDIA
POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 71: India Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 72: India Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 73: India 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 74: South Korea Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 75: South Korea Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 76: South Korea 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 77: Rest of Asia-Pacific Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 78: Rest of Asia-Pacific Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 79: Rest of Asia-Pacific 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
LATIN AMERICA
POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 80: Latin America Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 81: Latin America Historic Review for POC Lipid Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 82: Latin America 16-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 83: Latin America Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 84: Latin America Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 85: Latin America 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 86: Argentina Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 87: Argentina Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 88: Argentina 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
BRAZIL
TABLE 89: Brazil Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 90: Brazil Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 91: Brazil 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
MEXICO
TABLE 92: Mexico Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 93: Mexico Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 94: Mexico 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 95: Rest of Latin America Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 96: Rest of Latin America Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 97: Rest of Latin America 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
MIDDLE EAST
POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 98: Middle East Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 99: Middle East Historic Review for POC Lipid Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 100: Middle East 16-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 101: Middle East Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 102: Middle East Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 103: Middle East 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
IRAN
TABLE 104: Iran Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 105: Iran Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 106: Iran 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
ISRAEL
TABLE 107: Israel Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 108: Israel Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 109: Israel 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 110: Saudi Arabia Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 111: Saudi Arabia Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 112: Saudi Arabia 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 113: UAE Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 114: UAE Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 115: UAE 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 116: Rest of Middle East Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 117: Rest of Middle East Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 118: Rest of Middle East 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
AFRICA
POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 119: Africa Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 120: Africa Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 121: Africa 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030